China SXT Pharmaceuticals (SXTC) Interest Expenses (2019 - 2026)

China SXT Pharmaceuticals' Interest Expenses history runs 8 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 18.96% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 18.96% increase from a year earlier, with the FY2026 full-year figure at $1.7 million, up 18.96% from the prior year.
• Interest Expenses improved to $1.7 million in Q1 2026 per SXTC's latest filing, from $1.4 million in the prior quarter.
• Across five years, Interest Expenses topped out at $1.7 million in Q1 2026 and bottomed at $532368.0 in Q1 2022.
• The 5-year median for Interest Expenses is $1.3 million (2024), against an average of $1.2 million.
• Across the five-year window, Interest Expenses tumbled 51.19% in 2022 and soared 64.7% in 2023, its largest moves.
• Year by year, Interest Expenses stood at $532368.0 in 2022, then surged by 64.7% to $876804.0 in 2023, then surged by 42.58% to $1.3 million in 2024, then increased by 15.34% to $1.4 million in 2025, then gained by 18.96% to $1.7 million in 2026.
• Per Business Quant, the three latest SXTC Interest Expenses figures stand at $1.7 million (Q1 2026), $1.4 million (Q1 2025), and $1.3 million (Q1 2024).